Every other year screening for retinopathy

Article

Every other year screening for diabetic eye disease appears to be both safe and effective in patients with diabetes without retinopathy.

Every other year screening for diabetic eye disease appears to be both safe and effective in patients with diabetes without retinopathy, according to a report published online ahead of print by the British Journal of Ophthalmology.

Einar Stefánsson from the National University Hospital of Iceland and colleagues from the University of Iceland, reviewed 10-years experience of every other year screening for diabetics without retinopathy.

Of the 296 diabetic patients who had no diabetic retinopathy in 1994/1995, 172 did not develop retinopathy during the 10-year observation period. A total of 96 patients developed mild non-proliferative retinopathy, six developed clinically significant diabetic macular oedema, 23 developed pre-proliferative retinopathy and four developed proliferative diabetic retinopathy.

All the patients who did develop macular oedema or proliferative retinopathy had already been diagnosed with mild non-proliferative retinopathy and entered into an annual screening programme before sight threatening retinopathy developed. No patients experienced an undue delay in treatment.

According to the study, it would appear that screening for retinopathy in diabetic patients every other year is safe and effective and may help reduce unnecessary costs.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.